Beneficial effects of tea and its polyphenols against prostate cancer

被引:98
作者
Siddiqui, IA [1 ]
Adhami, VM [1 ]
Saleern, M [1 ]
Mukhtar, H [1 ]
机构
[1] Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA
关键词
chemoprevention; chemotherapy; epigallocatechin-3-gallate; green tea polyphenols; prostate cancer;
D O I
10.1002/mnfr.200500113
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Tea, next to water, is the most widely consumed beverage in the world. Depending upon the level of fermentation, tea can be categorized into three types: green (unfermented), oolong (partially fermented), and black (highly to fully fermented). In general, green tea has been found to be superior to black and oolong tea in terms of antioxidant and health promoting benefits owing to the higher content of (-)-epigallocatechin-3-gallate. Tea polyphenols comprise about one-third of the weight of the dried leaf, and they exhibit biochemical and pharmacological activities including antioxidant activities, inhibition of cell proliferation, induction of apoptosis, cell cycle arrest and modulation of carcinogen metabolism. Several studies demonstrate that most tea polyphenols exert their effects by scavenging reactive oxygen species (ROS) since excessive production of ROS has been implicated in the development of a variety of ailments including cancer of the prostate gland (CaP). Using cell culture and animal model systems, molecular targets for these remarkable beneficial effects of green tea drinking on CaP prevention and therapy have been defined. Geographical and case-control studies are showing that green tea drinking could afford CaP chemopreventive effects in human population. In this review we attempt to summarize the experimental as well as the epidemiological basis for the possible role of tea and its polyphenols for chemoprevention and chemotherapy of CaP.
引用
收藏
页码:130 / 143
页数:14
相关论文
共 177 条
[91]  
Ko Y, 2005, INT J MOL MED, V15, P183
[92]   Tea and cancer prevention: An evaluation of the epidemiologic literature [J].
Kohlmeier, L ;
Weterings, KGC ;
Steck, S ;
Kok, FJ .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1997, 27 (01) :1-13
[93]  
Koivisto P, 1997, J PATHOL, V183, P51, DOI 10.1002/(SICI)1096-9896(199709)183:1<51::AID-PATH1092>3.0.CO
[94]  
2-N
[95]  
Koivisto P, 1998, AM J PATHOL, V152, P1
[96]   Nutrition and prostate cancer [J].
Kolonel, LN .
CANCER CAUSES & CONTROL, 1996, 7 (01) :83-94
[97]  
Kono S, 1996, J Epidemiol, V6, P128
[98]   Dietary intervention in prostate cancer patients:: PSA response in a randomized double-blind placebo-controlled study [J].
Kranse, R ;
Dagnelie, PC ;
van Kemenade, MC ;
de Jong, FH ;
Blom, JHM ;
Tijburg, LBM ;
Weststrate, JA ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (05) :835-840
[99]   Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: Cellular transformation and invasion [J].
Kubota, S ;
Kiyosawa, H ;
Nomura, Y ;
Yamada, T ;
Seyama, Y .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (08) :567-571
[100]   To be, or not to be:: NF-κB is the answer -: role of Rel/NF-κB in the regulation of apoptosis [J].
Kucharczak, J ;
Simmons, MJ ;
Fan, YJ ;
Gélinas, C .
ONCOGENE, 2003, 22 (56) :8961-8982